Having acquired nearly all of Allergan’s generics business in a $40.5-billion blockbuster deal that was announced last year and closed on Aug. 2, Teva Pharma then announced the acquisition of Anda, Inc., an Allergan subsidiary that is the fourth-largest distributor of generic drugs in the US. Purchase price was $500 million; Anda’s 2016 revenue was projected to be $1.5 billion, and to add $0.15 to Teva’s earnings per share.
Anda distributes generic, brand, specialty and OTC pharma products from more than 300 manufacturers to retail independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics and physician offices across the United States, according to an Allergan statement. The company is headquartered in Weston, FL, and operates a distribution center from there as well as from Groveport, OH and Olive Branch, MS.
The deal further cements Allergan’s transformation into an innovator pharma company, which had changed when Actavis Pharma, a major generics producer, merged with the company in 2014 in a $66-billion deal (which also thwarted a competing bid from Valeant Pharma—dodged a bullet there, as later events transpired!). Analyst and press reports indicate that Anda has been a major customer of Teva products, which is no surprise since Teva is the leading global producer of generics.